Tafin Djoko, D.; Korneliou, A.; Belushkin, M.
Over the past few years, electronic cigarettes have rapidly evolved and have been introduced in multiple markets across the world. They are thought to be a potentially less harmful alternative to cigarettes, as they heat a liquid to generate the aerosol instead of combusting tobacco. Electronic cigarettes have different designs, with closed systems (such as cartridges), open systems, and variable power/temperature devices (mods). The aim of this study was to examine the aerosol emissions, with a focus on selected aldehydes of various e-cigarette designs from different markets. We performed the analyses until total liquid depletion to test the products’ consistency. To put the results into perspective, the aerosol constituents of e-cigarettes were compared with smoke from the 3R4F reference cigarette. The selected aldehydes (formaldehyde, acetaldehyde and acrolein) known to result from a temperature dependent oxidation of the aerosol formers, glycerol and propylene glycol, commonly used in e-cigarettes were detectable in most products, with the lowest levels observed in closed systems. Generally higher levels were observed in open systems and especially in mods, operated in different conditions in terms of power output, product orientation on the puffing machine or puffing regimes. The need for standardization work on the assessment of variable power electronic cigarettes is emphasized.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.